<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="//merztherapeutics.com/ch/wp-content/plugins/wordpress-seo/css/main-sitemap.xsl"?>
<urlset xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:image="http://www.google.com/schemas/sitemap-image/1.1" xsi:schemaLocation="http://www.sitemaps.org/schemas/sitemap/0.9 http://www.sitemaps.org/schemas/sitemap/0.9/sitemap.xsd http://www.google.com/schemas/sitemap-image/1.1 http://www.google.com/schemas/sitemap-image/1.1/sitemap-image.xsd" xmlns="http://www.sitemaps.org/schemas/sitemap/0.9">
	<url>
		<loc>https://merztherapeutics.com/ch/communique-de-presse-teijin-obtient-lappobation-de-mise/</loc>
		<lastmod>2022-11-17T09:53:52+00:00</lastmod>
	</url>
	<url>
		<loc>https://merztherapeutics.com/ch/communique-de-presse-teijin-obtient-une-approbation-supplementaire-au-japon/</loc>
		<lastmod>2022-11-17T09:55:38+00:00</lastmod>
	</url>
	<url>
		<loc>https://merztherapeutics.com/ch/communique-de-presse-merz-et-la-start-up-israelienne-vensica-lancent-un-partenariat/</loc>
		<lastmod>2022-11-17T09:57:08+00:00</lastmod>
	</url>
	<url>
		<loc>https://merztherapeutics.com/ch/communique-de-presse-xeomin/</loc>
		<lastmod>2022-11-17T09:58:03+00:00</lastmod>
	</url>
	<url>
		<loc>https://merztherapeutics.com/ch/pressemitteilung-merz-und-das-israelische-start-up-venisca-schliessen-partnerschaft-fuer-nadellose-reizblasenbehandlung/</loc>
		<lastmod>2022-12-02T17:10:01+00:00</lastmod>
	</url>
	<url>
		<loc>https://merztherapeutics.com/ch/xeomin-incobotulinumtoxina-erhaelt-europaeische-zulassung-fuer-die-behandlung-der-chronischen-sialorrhoe-bei-kindern/</loc>
		<lastmod>2022-12-04T21:37:22+00:00</lastmod>
	</url>
	<url>
		<loc>https://merztherapeutics.com/ch/teijin-erhaelt-erweiterte-marktzulassung-fuer-xeomin-incobotulinumtoxina-von-merz-in-japan/</loc>
		<lastmod>2022-12-04T21:48:15+00:00</lastmod>
	</url>
	<url>
		<loc>https://merztherapeutics.com/ch/teijin-erhaelt-die-japanische-marktzulassung-fuer-xeomin-botulinum-neurotoxin-typ-a-von-merz/</loc>
		<lastmod>2022-12-04T21:48:58+00:00</lastmod>
	</url>
	<url>
		<loc>https://merztherapeutics.com/ch/xeomin-incobotulinumtoxina-erhaelt-zulassung-fuer-neue-therapeutische-indikation-in-der-schweiz/</loc>
		<lastmod>2024-06-14T07:11:40+00:00</lastmod>
	</url>
	<url>
		<loc>https://merztherapeutics.com/ch/parkinson-swissmedic-autorise-inbrija-une-levodopa-par-inhalation/</loc>
		<lastmod>2026-10-15T15:31:07+00:00</lastmod>
	</url>
	<url>
		<loc>https://merztherapeutics.com/ch/swissmedic-laesst-inbrija-zu-inhalatives-levodopa-bei-parkinson/</loc>
		<lastmod>2026-10-15T15:32:05+00:00</lastmod>
	</url>
</urlset>
<!-- XML Sitemap generated by Yoast SEO -->